MedTrace Logo

Correlation Between Q-value Changes and Progression of Pediatric Keratoconus.

NCT05114928 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 9

Last updated 2021-11-10

No results posted yet for this study

Summary

Keratoconus is a progressive corneal disease characterized by asymmetric corneal thinning and structural changes in corneal collagen which leads to decrease in visual acuity due to myopic shift, irregular astigmatism or corneal scarring. Early detection of the disease in children aids in halting the progression and improve their quality of life. There is no consensus regarding the progression criteria of the disease, we aimed to assess the changes in corneal asphericity in children after corneal collagen crosslinking and investigate any possible correlation with progression criteria widely used.

Conditions

  • Keratoconus
  • Collagen Diseases
  • Corneal Disease

Interventions

PROCEDURE

Transepithelial Corneal Collagen Cross-linking

Bilateral Transepithelial Corneal Collagen Cross-linking was done for all subjects using power of 9mW/cm2 at 55mm from the cornea for 10 minutes, with a total energy of 5.4j/cm2 using the (CCL VARIO, PESCHKE Trade GmbH, Huenenberg Switzerland), in the period between January 2016 to August 2016.

DIAGNOSTIC_TEST

Scheimpflug camera

Pentacam (OCULUS Optikgeräte GmbH, Wetzlar, Germany) was done for all subjects at baseline and annually after TE-CXL till 5 years of follow-up.

Sponsors & Collaborators

  • Benha University

    lead OTHER

Principal Investigators

  • Ahmed A Tabl, MD · Benha University

Eligibility

Min Age
6 Years
Max Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-09
Primary Completion
2021-10-25
Completion
2021-10-28

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05114928 on ClinicalTrials.gov